Pharma major Lupin Limited announced on Friday that United States Food and Drug Administration (USFDA) had given the company approval for its Trientine Hydrochloride capsules USP, 250 mg. The company will now be able to market a generic equivalent of Syprine capsules, 250 mg of Bausch Health US, LLC.